Navigation Links
Novartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
Date:11/6/2011

.

"These data demonstrate the significant benefits that ACZ885 may provide this young population, both in steroid reduction and in extending the period these children can live free from SJIA flares," said David Epstein, Head of the Pharmaceuticals Division of Novartis. "Novartis is committed to helping improve the health of patients with SJIA and other inflammatory diseases, which is why we are delighted to be sharing these results."

ACZ885 is an investigational fully human monoclonal antibody which neutralizes the key inflammatory mediator, interleukin-1 beta (IL-1 beta), which plays an important role in a number of diseases including SJIA[5].

The incidence of SJIA is estimated to be less than 1 in 100,000 children[6]. It is called 'systemic' because the inflammation affects the whole body, as well as most of the joints[4]. The condition is characterized by potentially life-long, recurrent and painful arthritis flares, skin rashes and daily spiking fevers[2],[4].

Novartis is also presenting a number of other studies at ACR, including a second pivotal Phase III trial of ACZ885 in SJIA, which was previously presented at the 2011 European Pediatric Rheumatology Congress in Bruges, Belgium, in September.

About the StudyThe Phase III, two-part study had an open-label, single-arm active treatment in Part I followed by a randomized, double-blind, placebo-controlled, event-driven withdrawal design in Part II[1]. A total of 177 patients between the ages of 1 and 19 years with active SJIA were enrolled in the study[1]. In Part I, patients received a subcutaneous (s.c.) dose of ACZ885 (4 mg/kg, up to 300 mg) every 4 weeks. After 8 weeks, patients who met the adapted ACR Pediatric 30 criteria began tapering (reducing) their steroid use until either: a) the dose had been decreased to less than or equal to 0.5 mg/kg[7] while maintaining the adapted ACR Pediatric 30 Criteria (successful tapering of steroids); or b)
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
2. Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe
3. Nektar Sells Pulmonary Business to Novartis For $115 Million and Nektar Retains Key Pulmonary Programs Including Amikacin Inhale, Inhaled Vancomycin, and Ciprofloxacin Inhalation Powder
4. Nektar Announces Closing of Sale of Specific Pulmonary Delivery Assets to Novartis for $115 Million
5. Physicians in Europe Rate Novartis #1 on Service Delivery, While Merck Earns Top Honors in the US
6. Novartis/Schering-Ploughs Drug Will Replace AstraZenecas Symbicort as Decision Resources Clinical Gold Standard by 2012 for the Treatment of Asthma
7. Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
8. Photo: Novartis Receives FDA Approval for Valturna(R), a Single-Pill Combination of valsartan and aliskiren, to Treat High Blood Pressure
9. Heptares Therapeutics Announces Agreement With Novartis Option Fund to Apply its StaR(TM) Technology and Generate Novel Drug Leads Against a GPCR Target
10. Novartis Class Awarded $250 Million in Punitive Damages
11. Silence Therapeutics Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... According to Jeff Howell, Partner of ... Global, new development in Downtown Toronto is expanding at ... another 755 storeys of new development last week (including ... be dominating the Toronto skyline for the foreseeable future ... thirst for new development. , As the Toronto city ...
(Date:9/15/2014)... , Sept. 15, 2014 ... on revolutionizing the treatment of cancer through the ... cells, announced that, together with the Asbestos Disease ... Cancer Institute New South Wales (NSW) Premier,s Award ... four recipients are the hospitals that will be ...
(Date:9/15/2014)... led by Northeastern University has developed a novel ... a variety of nanocarbon structures in carbon nanotube ... which will allow the researchers to tailor the ... applications ranging from electronic devices to CNT-reinforced composite ... equipment. , Their findings were published in the ...
(Date:9/15/2014)... AUSTIN, Texas , Sept. 15, 2014 The ... changes in climate, says a new article published by the ... Ahmed , PhD, on climate change and its effects on ... part of an extensive study conducted by Dr. Ahmed in ... China and has implications for the future ...
Breaking Biology Technology:ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 2ITRA Global Reports Downtown Toronto Real Estate Development is in High Gear 3EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 2EnGeneIC Named a Recipient of the Cancer Institute NSW Premier's Award for Excellence in Translational Cancer Research 3Northeastern University Researchers Develop Novel Method for Working with Nanotubes 2Tea Taste and Quality Affected by Climate Change 2Tea Taste and Quality Affected by Climate Change 3Tea Taste and Quality Affected by Climate Change 4
... , NOVATO, Calif., Sept. 8 BioMarin Pharmaceutical Inc. ... Officer of BioMarin, will present a company update at the Morgan Stanley ... 1:35 p.m. ET. , , Interested parties ... investor section of the BioMarin website, www.BMRN.com . ...
... , SAN DIEGO, Sept. 8 eBioscience Corporation, a ... the acquisition of NatuTec GmbH, a leading distributor of high-quality biological ... , "For the past 10 years, NatuTec has ... R. Nelson, CEO of eBioscience. "The NatuTec acquisition provides eBioscience ...
... LAIYANG, China, Sept. 8 /PRNewswire-Asia-FirstCall/ -- ... a,U.S. pharmaceutical company with its principal operations in the ... for,fiscal year 2009. The Company expects to meet ... revenue and operating income of $40 to $43 million ...
Cached Biology Technology:BioMarin to Present at the Morgan Stanley Healthcare Conference 2eBioscience Corporation Acquires NatuTec GmbH 2Jiangbo Pharmaceuticals Reaffirms Guidance for Fiscal 2009 2
(Date:9/16/2014)... YORK (17 September, 2014)More than $100 trillion in ... of annual carbon dioxide (CO2)a 40 percent reduction ... 2050 if the world expands public transportation, walking ... report released by the University of California, Davis, ... (ITDP). , Further, an estimated 1.4 million ...
(Date:9/16/2014)... its own bacterial identity. That,s the conclusion of University ... studied the genetic fingerprints of bacteria on 57 species ... study demonstrates for the first time that host plants ... possess very different microbial communities on their leaves," said ... in the UO,s Institute of Ecology and Evolution who ...
(Date:9/16/2014)... the Keystone XL pipeline (KXL) would likely increase oil ... researchers surveyed by the non-profit organization Near Zero. The ... Climate Impact," and includes both supporters and opponents of ... oil sands could lead to significantly higher greenhouse gas ... markets respond. , "This report examines three main ...
Breaking Biology News(10 mins):Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2Keystone XL would likely raise oil sands production and greenhouse gas emissions 2
... For the first time in nearly a century drinkers will ... heritage barley from the Victorian period. Old varieties ... the John Innes Centre revived Chevallier from the institute,s Genetic ... records indicate that the variety produced premium quality malt and ...
... analysis, carbon dioxide removal could be used under certain ... but it would not replace the bulk of actual ... allows to separate emissions control from the time and ... important for climate protection," says lead-author Elmar Kriegler. "You ...
... "Many of the great whales which once populated the oceans ... commercial hunting. The committee also worried about how tuna fishing ... And they considered reports about seal hunting and the decline ... October of that year, Congress passed the Marine Mammal Protection ...
Cached Biology News:Cheers to better beer and disease resistance 2CO2 removal can lower costs of climate protection 2CO2 removal can lower costs of climate protection 3Sea mammals find US safe harbor 2Sea mammals find US safe harbor 3Sea mammals find US safe harbor 4
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
Polyclonal antiserum raised against conjugated L-isoleucine. Available as antiserum. Amino Acid Antibodies...
... in heart tissues, and is produced ... conditions. Treatment of cells with ... TIMP-4 in some cell types, but ... require concentration of cell culture media ...
Mouse monoclonal [002-49] to C1s ( Abpromise for all tested applications). entrezGeneID: 716 SwissProtID: P09871...
Biology Products: